Intelligence Feed event · Equity · 2026-09-12

    Cellectis Schedules September 14 Business and CAR T Pipeline Update

    Question

    Cellectis Schedules September 14 Business and CAR T Pipeline Update

    Direct answer

    Clinical-stage biotechnology developer Cellectis announced a corporate conference call and webcast on September 14, 2026, to present an operational update across its gene editing and CAR T cell therapy pipeline. The presentation represents a key informational catalyst regarding the company's clinical trial progress and operational execution.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Cellectis Schedules September 14 Business and CAR T Pipeline Update”, revision 1, evidence through 2026-09-12. https://marketontology.com/market-events/2026-09-12/cellectis-schedules-september-14-business-and-car-t-pipeline-update-872f2c

    EQUITY
    Cellectis Schedules September 14 Business and CAR T Pipeline Update
    Clinical-stage biotechnology developer Cellectis announced a corporate conference call and webcast on September 14, 2026, to present an operational update across its gene editing and CAR T cell therapy pipeline. The presentation represents a key informational catalyst regarding the company's clinical trial progress and operational execution.
    CLLS
    Impact
    55
    SEP 12
    SIG
    90%
    CLLS
    Cellectis Schedules September 14 Business and CAR T Pipeline Update
    Clinical-stage biotechnology developer Cellectis announced a corporate conference call and webcast on September 14, 2026, to present an operational update across its gene editing and CAR T cell therapy pipeline. The presentation represents a key informational catalyst regarding the company's clinical trial progress and operational execution.
    → Upcoming pipeline guidance provides clinical milestone timing for allogeneic CAR T assets, determining CLLS cash runway projections.
    Impact
    Clinical-stage biotechnology developer Cellectis announced a corporate conference call and webcast on September 14, 2026, to present an operational update across its gene editing and CAR T cell therapy pipeline. The presentation represents a key informational catalyst regarding the company's clinical trial progress and operational execution.
    Affected
    CLLS
    Transmission
    Upcoming pipeline guidance provides clinical milestone timing for allogeneic CAR T assets, determining CLLS cash runway projections.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    CLLSclinical pipeline milestones and operational runway disclosureWatch1-5dCellectis scheduled business update conference call for September 14, 2026.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month